valsartan has been researched along with Colorectal Cancer in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Asgharzadeh, F; Avan, A; Hashemzehi, M; Hassanian, SM; Khazaei, M; Mostafapour, A; Naghibzadeh, N | 1 |
| Amerizadeh, F; Asgharzadeh, F; Avan, A; Ebrahimi, S; Fakhraei, M; Farshbaf, A; Ferns, GA; Giovannetti, E; Hassanian, SM; Khazaei, M; Mostafapour, A; Sabbaghzadeh, R | 1 |
| Ernst, MT; Hallas, J; Johansen, NB; Kristensen, KB; Pottegård, A; Quartarolo, P | 1 |
3 other study(ies) available for valsartan and Colorectal Cancer
| Article | Year |
|---|---|
Angiotensin II Receptor Antagonist, Valsartan, Has Beneficial Effect in Lung Metastasis of Colorectal Cancer Treated with Fluorouracil.
Topics: Angiotensin Receptor Antagonists; Animals; Colorectal Neoplasms; Fluorouracil; Humans; Lung Neoplasms; Valsartan | 2023 |
Inhibition of angiotensin pathway via valsartan reduces tumor growth in models of colorectal cancer.
Topics: Angiotensins; Animals; Colorectal Neoplasms; Fluorouracil; Matrix Metalloproteinase 2; Mice; Valsartan | 2022 |
Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: Danish nationwide cohort study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Cohort Studies; Colorectal Neoplasms; Denmark; Dimethylnitrosamine; Drug Contamination; Female; Humans; Male; Middle Aged; Neoplasms; Risk Factors; Uterine Neoplasms; Valsartan | 2018 |